

n=1401 patients

14 Day-
trial 2003
n=542

28-Day trial
2005-2007
n=859

Study I
n=187

Study II
n=176

Study III
n=179

2005
n=249

2006
n=427

2007
n=183

AQ, n=64**
62*/63§+

AQ, n=58
52/54

AQ, n=58
57/58

Study I
n=185

Study I
n=136

AS-AQ
73/81/92

SP, n=61
53/61

SP, n=57
48/53

SP, n=61
52/57

AQ, n=64**
50*/55§/59§+

AQ-SP, n=67
55/62/62

DH-PP
84/84/91

AQ-SP, n=62
59/59

AQ-SP, n=61
59/59

AQ-SP, n=60
58/58

AS-AQ, n=60
43/53/54

AS-MQ, n=69
60/61/61

Study II §++
n=64

Study II
n=123

AS-AQ, n=62
52/55/57

AS-AQ
58/-/58

AM-LM, n=61
58/60/60

Study III
n=168

AS-CD, n=83
53/60/71

AS-SP, n=85
73/74/79